Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:09:33 2025-02-14 EST			5-day change	1st Jan Change
83.02 ^USD	-1.65%		-4.88%	-16.55%

02-13	Merck & Co. Insider Sold Shares Worth $512,057, According to a Recent SEC Filing	MT
02-13	Pending US vaccine decisions as Kennedy takes top health job	RE

Merck & Co., Inc. Provides Earnings Guidance for the Full Year 2025

February 04, 2025 at 06:30 am

Merck & Co., Inc. provided earnings guidance for the full year 2025. For the period, the company anticipates full-year sales to be between $64.1 billion and $65.6 billion, including a negative impact of foreign exchange of approximately 2% at mid-January 2025 exchange rates.

Latest news about Merck & Co., Inc.

Merck & Co. Insider Sold Shares Worth $512,057, According to a Recent SEC Filing	02-13	MT
Pending US vaccine decisions as Kennedy takes top health job	02-13	RE
RFK Jr. Confirmed as HHS Head by Senate, Bloomberg Reports	02-13	MT
RFK Jr. Confirmed as HHS Head by Senate	02-13	MT
Guggenheim Adjusts Price Target on Merck & Co. to $115 From $122	02-12	MT
HD announced that it has received $7.8 million in funding from Merck & Co., Inc., SBI Ven Capital Pte. Ltd., M Venture Partners Pte. Ltd., Febe Ventures Limited, Partech Partners SAS	02-11	CI
HSBC Adjusts Price Target on Merck to $115 From $130	02-11	MT
Merck Says Health Canada Approves Keytruda for Non-Small Cell Lung Cancer	02-11	MT
Health Canada Approves Merck's KEYTRUDA® (Pembrolizumab) for the Treatment of Adult Patients with Respirable Non-Small Cell Lung Cancer	02-11	CI
Bernstein Adjusts Price Target on Merck & Co. to $95 From $110, Keeps Market Perform Rating	02-11	MT
TD Cowen Downgrades Merck & Co. to Hold From Buy, Adjusts Price Target to $100 From $121	02-10	MT
Health Rounds: Vaccine keeps advanced kidney cancer from recurring	02-07	RE
Trump faces pressure from US industry over China tariff on medicines	02-06	RE
Merck Initiates Phase 3 Trial of Zilovertamab Vedotin Antibody-Drug Conjugate to Treat Lymphoma	02-06	MT
Merck: launch of a phase 3 study in lymphoma	02-06	CF
Merck Announces Phase 3 Waveline-010 Trial Initiation Evaluating Zilovertamab Vedotin, an Investigational Antibody-Drug Conjugate, for the Treatment of Patients with Previously Untreated Diffuse Large B-Cell Lymphoma	02-06	CI
UBS Adjusts Price Target on Merck to $105 From $120, Maintains Buy Rating	02-05	MT
Wells Fargo Adjusts Merck Price Target to $97 From $110	02-05	MT
Citigroup Adjusts Merck Price Target to $115 From $125	02-05	MT
Jefferies Adjusts Merck Price Target to $138 From $150	02-05	MT
JPMorgan Adjusts Merck Price Target to $130 From $145	02-05	MT
Daiwa Securities Adjusts Merck Price Target to $95 From $100	02-05	MT
Goldman Sachs Adjusts Merck Price Target to $129 From $135	02-05	MT
Leerink Partners Adjusts Merck Price Target to $113 From $118	02-05	MT
Deutsche Bank Adjusts Merck Price Target to $128 From $132, Maintains Buy Rating	02-05	MT

Chart Merck & Co., Inc.

Duration

Period

MRK: Dynamic Chart

Company Profile

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

71,000

Sector

Pharmaceuticals

Calendar

2025-03-16 - Détachement de

More about the company